Oyster Point Pharma, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2015-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.oysterpointrx.com
A Study Evaluating the Safety of the Nasal Pump
- First Posted Date
- 2024-03-26
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT06329687
- Locations
- 🇺🇸
United States, California, Newport Beach, California, United States
Phase 4 Study Evaluating the Safety of the Nasal Guide With Tyrvaya
Phase 4
Completed
- Conditions
- Dry EyeKeratoconjunctivitis Sicca
- Interventions
- Combination Product: Nasal Guide
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05918406
- Locations
- 🇺🇸
United States, New Jersey, Woodland Park, New Jersey, United States
Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy
Phase 2
Completed
- Conditions
- Neurotrophic Keratopathy
- Interventions
- Drug: OC-01 (varenicline) nasal spray 1.2 mg/mlDrug: Placebo (vehicle) nasal spray
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 113
- Registration Number
- NCT04957758
- Locations
- 🇺🇸
Danbury, Connecticut, Danbury, Connecticut, United States
🇺🇸Boston Massachusetts, Boston, Massachusetts, United States
🇺🇸Houston Texas, Houston, Texas, United States
Evaluating Relative Bioavailability of OC-01 (Varenicline) Nasal Spray as Compared to Orally Administered Varenicline
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: OC-01 (varenicline solution) nasal spray 0.12 mg then Varenicline oral tablet 1 mgDrug: Vaenicline oral tablet 1 mg, then OC-01 (varenicline solution) nasal spray 0.12 mg
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT04072146
- Locations
- 🇺🇸
United States, Miami Florida, Miami, Florida, United States
Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Phase 3
Completed
- Conditions
- Dry Eye Disease (DED)
- Interventions
- Drug: OC-01 (varenicline) nasal sprayDrug: Placebo (vehicle) nasal spray
- First Posted Date
- 2019-07-29
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 758
- Registration Number
- NCT04036292
- Locations
- 🇺🇸
Delray Beach, Delray Beach, Florida, United States
🇺🇸San Antonio, San Antonio, Texas, United States
🇺🇸Lynchburg, Lynchburg, Virginia, United States
Evaluation of the Long Term Follow up of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Phase 2
Completed
- Conditions
- Long Term Follow up Dry Eye Disease
- Interventions
- Drug: OC-01 Mid Dose, 0.6 mg/mLDrug: Placebo (vehicle) nasal sprayDrug: OC-01 Low Dose, 0.12 mg/mLDrug: OC-01 High Dose, 1.2 mg/mL
- First Posted Date
- 2019-04-18
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 101
- Registration Number
- NCT03920215
- Locations
- 🇺🇸
Newport Beach, Newport Beach, California, United States
🇺🇸Indianapolis, Indianapolis, Indiana, United States
🇺🇸Andover, Andover, Massachusetts, United States
Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)
Phase 2
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: OC-01 0.1% 0.6 mg/mlOther: placebo comparator
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2022-06-08
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 123
- Registration Number
- NCT03873246
- Locations
- 🇲🇽
Mexico City, Mexico City, Mexico
Efficacy of OC-01 Nasal Spray on Goblet Cell and Meibomian Gland Stimulation
Phase 2
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: OC-01 (varenicline) nasal sprayDrug: Placebo (vehicle control) nasal spray
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2021-12-29
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03688802
- Locations
- 🇺🇸
Tufts, Boston, Massachusetts, United States
Evaluation of the Efficacy of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease
Phase 2
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: OC-01 (varenicline) nasal sprayDrug: Placebo (vehicle) nasal spray
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2021-10-25
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 182
- Registration Number
- NCT03636061
- Locations
- 🇺🇸
Newport Beach, Newport Beach, California, United States
🇺🇸Indianapolis, Indianapolis, Indiana, United States
🇺🇸Andover, Andover, Massachusetts, United States
Evaluation of the Efficacy of OC-02 Nasal Spray on Signs and Symptoms of Dry Eye Disease (the RAINIER Study)
Phase 2
Completed
- Conditions
- Dry Eye Disease
- Interventions
- Drug: OC-02 (simpinicline) nasal sprayDrug: Placebo (vehicle) nasal spray
- First Posted Date
- 2018-08-16
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Oyster Point Pharma, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT03633461
- Locations
- 🇺🇸
Louisville, Louisville, Kentucky, United States
🇺🇸Nashville, Nashville, Tennessee, United States
© Copyright 2025. All Rights Reserved by MedPath